BlackRock, Inc. 13D and 13G filings for Apellis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 5:31 pm Unchanged |
2024-09-30 | 13G | Apellis Pharmaceuticals, Inc. APLS |
BlackRock Inc. BLK |
6,191,937 5.100% |
0 (Unchanged) |
Filing |
| 2024-10-18 3:31 pm Purchase |
2024-09-30 | 13G | Apellis Pharmaceuticals, Inc. APLS |
BlackRock Inc. BLK |
6,191,937 5.100% |
444,753 (+7.74%) |
Filing |
| 2023-07-07 4:35 pm Sale |
2023-06-30 | 13G | Apellis Pharmaceuticals, Inc. APLS |
BlackRock Inc. BLK |
5,747,184 4.900% |
-1,957,010 (-25.40%) |
Filing |
| 2023-01-31 5:52 pm Purchase |
2022-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS |
BlackRock Inc. BLK |
7,704,194 7.000% |
1,838,482 (+31.34%) |
Filing |
| 2022-02-03 4:41 pm Sale |
2021-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS |
BlackRock Inc. BLK |
5,865,712 6.100% |
-149,236 (-2.48%) |
Filing |
| 2021-02-05 07:51 am Purchase |
2020-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS |
BlackRock Inc. BLK |
6,014,948 7.900% |
1,257,443 (+26.43%) |
Filing |